Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic vaccination against active tuberculosis

a technology of active tuberculosis and therapeutic vaccination, applied in the field of biotechnology and health care, can solve the problems of not being able to recognize and kill intracellular tb organisms, and achieve the effect of reducing the burden of mtb

Inactive Publication Date: 2014-10-30
JANSSEN VACCINES & PREVENTION BV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a new vaccine that is safe and effective in protecting against tuberculosis (TB). The vaccine contains genetic material from the bacteria that causes TB and is delivered using a recombinant adenovirus vector. The vaccine was found to be safe and to overcome the immune suppression caused by the bacteria. The study also showed that the vaccine can reduce the duration of TB treatment and help prevent relapses. The bacterial burden was found to be lower in patients who received the vaccine compared to those who did not.

Problems solved by technology

The induction of such tolerance paralyzes the immune system in an antigen-specific manner so that it is not able to recognize and kill intracellular TB organisms that chemotherapeutic agents have little access to.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic vaccination against active tuberculosis
  • Therapeutic vaccination against active tuberculosis
  • Therapeutic vaccination against active tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Clinical Trial with Ad35-Based TB Vaccine (Ad35.TB-S) in Human Subjects

[0092]A randomized, double-blinded, placebo-controlled clinical trial on human subjects was performed to evaluate the safety and immunogenicity of Ad35.TB-S (Havenga et al., 2006; Rado{hacek over (s)}ević et al., 2007; WO 2006 / 053871) in individuals with prior or current tuberculosis. This trial was conducted to ensure that the vaccine did not elicit severe adverse reactions, such as Koch's phenomenon, in subjects with previously unrecognized or active tuberculosis. By ensuring the safety of the vaccine in patients clinically documented to have tuberculosis, the vaccine could then be administered widely to larger populations in future studies without the need for extensive TB testing among subjects.

[0093]The study was designed as a dose escalation study where the vaccine dosage was increased in successive patient groups. Patients were enrolled sequentially, with the patients receiving the lowest dosage of vaccine...

example 2

Proof of Concept Study to Show the Treatment-Shortening Effect of the Ad35.TB-S Vaccine on Tuberculosis Drug Therapy in Mice

[0099]Here, a method to show the TB chemotherapy-shortening effect of Ad35.TB-S is described. The method utilizes an established mouse model for TB drug chemotherapy, which is adapted for experimentation with the Ad35.TB-S vaccine.

[0100]Treatment of humans with Isoniazid, Rifampicin and Pyrazinamide in the first two months followed by Rifampicin and Isoniazid for the remaining four months of therapy results in a 1% to 2% chance of disease relapse (Neurmberger, 2008; Fox et al., 1999). In mice, similar therapy results in a 0% to 10% chance of relapse (Neurmberger, 2008). In a recent study, BALB / C mice exhibited a 0% relapse proportion when treated with this six-month standard regimen, which rose to 90% when treatment was shortened to four months (Williams et al., 2009). In that study, “relapse” was defined as isolation of 1 or greater CFU after plating the entir...

example 3

The Effect of Therapeutic Vaccination by Heterologous Boosting of Ad35.TB-S with Ad26.TB-S Vaccines in a Mouse Model of TB Therapy

[0107]The first heterologous prime-boost vaccine was trialed in humans by the group of Adrian Hill at Oxford (Schneider et al., 1998) in a trial designed to study the immunogenicity of a prophylactic vaccine against malaria. It was then observed that priming and boosting with different vectors carrying the same antigens resulted in a markedly enhanced immune response, which was due to the proliferation of memory T cells.

[0108]To test if priming with Ad35 and boosting with Ad26 would markedly result in enhanced immunogenicity as well as a decrease in relapse proportions upon shortening of TB therapy, two additional arms were added to the study shown in Example 2 (FIG. 6). In one arm, an additional vaccination of Ad26.TB-S containing the same antigens as the Ad35.TB-S was given at the end of the four-month therapy. Should the Ad26.TB-S boost enhance the imm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for therapeutic treatment of a patient having active tuberculosis (TB), the method comprising: administering to the patient a recombinant adenovirus vector that comprises nucleic acid encoding the Ag85A, Ag85B and TB10.4 antigens of Mycobactium tuberculosis (Mtb). Advantageously, the method can be used to shorten conventional drug therapy for treating active TB.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of co-pending U.S. patent application Ser. No. 13 / 822,593, filed Mar. 12, 2013, which is a national phase entry under 35 U.S.C. §371 of International Patent Application PCT / EP2011 / 066183, filed Sep. 19, 2011, designating the United States of America and published in English as International Patent Publication WO 2012 / 038367 A1 on Mar. 29, 2012, which claims the benefit under Article 8 of the Patent Cooperation Treaty and under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 61 / 403,751, filed Sep. 20, 2010, and under Article 8 of the Patent Cooperation Treaty to European Patent Application Serial No. 10177667.2, filed Sep. 20, 2010, the contents of each of which are incorporated herein by reference.TECHNICAL FIELD[0002]The disclosure relates to the field of biotechnology and health care. More particularly, it concerns methods for therapeutic vaccination of subjects having act...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/04A61K45/06
CPCA61K39/04A61K2039/57A61K2039/5254A61K45/06A61K2039/5256A61K2039/53A61K2039/545C07K14/35A61P31/06A61K31/133A61K31/455A61K31/496A61K31/4965
Inventor SADOFF, JERALD CHARLESALYAHYA, ANISAH
Owner JANSSEN VACCINES & PREVENTION BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com